Analytical Data
-
Gene name
HLA-A*03:01&B2M&KRAS G12V(VVGAVGVGK) Monomer
- Application
-
Alternative Names
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&VVGAVGVGK
-
Molecular Weight
56-65 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*03:01/B2M/KRAS G12V (VVGAVGVGK) monomeric recombinant protein is situated at the intersection of immunology and cancer research. Human Leukocyte Antigen (HLA) molecules are crucial for the presentation of tumor-associated antigens to T cells, playing a significant role in immune response against tumors. The HLA-A*03:01 allele is one of the most common HLA class I molecules, and its interactions with specific peptides can influence the effectiveness of anti-tumor immunity. KRAS mutations, particularly the G12V variant, are prevalent in various cancers, leading to aberrant signaling pathways that promote tumorigenesis. The 9-mer peptide VVGAVGVGK represents a specific epitope derived from the mutated KRAS, which can elicit T cell responses. Researching the HLA-A*03:01/B2M/KRAS G12V monomer enhances our understanding of the immune landscape in tumors harboring this mutation. By characterizing this recombinant protein, we can potentially identify therapeutic strategies that harness the immune system to target KRAS-driven tumors effectively. This work may pave the way for the development of personalized cancer vaccines or adoptive T cell therapies that target KRAS mutations, addressing the significant challenge these alterations pose in oncology. Furthermore, understanding the structural and functional aspects of this complex can help elucidate mechanisms of immune evasion in tumors, contributing to the broader field of cancer immunotherapy.
